This study has reported a potential therapeutic application of the newfound C70PLY4 peptide, a truncated form of PLY, in anti-chronic inflammatory disease, including atherosclerosis, in HFD/STZ-induced inflammatory rat models, which might be achieved via inhibiting TLR4 activity by competing with MD2 for its binding site on TLR4. The gene discussed is LY96; the disease is atherosclerosis.